CTIS2024-514358-56-00进行中（未招募）1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.
abo'Life Belgium0 个研究点目标入组 140 人开始时间: 2024年5月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Man or woman aged 16-80 years, - Patient presenting 6 or more episodes of orofacial herpes infections during the preceding 12-months’ period (prior to the study entry), - Woman of childbearing age under effective contraception, - Patient reporting a current stable sexual relationship (steady sexual partner during study duration), - Patient having faculties to understand and respect the constraints of the study, - Signature of the Informed Consent Form.
排除标准
- •- Pregnant or breastfeeding woman, - Patient under immunotherapy (including immunosuppressive treatment) or microimmunotherapy received during last previous 6 months, - Patient who had a suppressive antiviral therapy during last month, - Patient who wishes to continue his/her suppressive antiviral therapy, - Patient with known lactose intolerance, - Patient who participated in a clinical study in the previous 3-month period, - Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study, - Patient with severe immunodeficiency disease requiring long term treatment (*) or under chemotherapy or radiotherapy or corticoid therapy, - Patient under listed homeopathic or phytotherapy treatment, - Patient using or addicted to recreational drugs. (*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.
研究者
相似试验
进行中（未招募）
不适用
Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4EUCTR2005-003870-88-DEMukoviszidose Institut gGmbH i. G.160
招募中
4 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.2024-514358-56-00Labo'Life Belgium140
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LVERU®JUNIOR and 2LVERU® on the treatment of warts. EVAsION Studyon genital warts infectionMedDRA version: 21.1Level: LLTClassification code: 10010115Term: Common warts Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10035158Term: Plantar warts Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10047828Term: Warts Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10035150Term: Planar warts Class: 10029104CTIS2024-514476-40-00abo'Life Belgium162
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infectioEpstein-Barr Virus infectionMedDRA version: 21.0Level: LLTClassification code: 10056907Term: EBV antigen positive Class: 10022891MedDRA version: 21.1Level: LLTClassification code: 10056906Term: EBV antibody positive Class: 10022891MedDRA version: 23.1Level: LLTClassification code: 10014078Term: EBV infection reactivation Class: 10021881MedDRA version: 20.0Level: LLTClassification code: 10014077Term: EBV infection Class: 10021881CTIS2024-514222-24-00abo'Life Belgium88
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LPAPI® on the clearance of high-risk oncogenic HPV genital infections (PAPION study)MedDRA version: 25.0Level: LLTClassification code: 10086966Term: HPV screening Class: 100000004848MedDRA version: 25.0Level: LLTClassification code: 10086964Term: HPV infection Class: 100000004848MedDRA version: 20.0Level: SOCClassification code: 10038604Term: Reproductive system and breast disorders Class: 20MedDRA version: 20.0Level: SOCClassification code: 10021881Term: Infections and infestations Class: 1Human Papillomavirus infectionCTIS2024-513969-39-00abo'Life Belgium284